联邦制药盘中涨超6%，截至发稿，股价上涨4.08%，现报17.18港元，成交额1.99亿港元。近日，联邦制药发布2025年上半年业绩。中金指出，25H1公司营业收入75.19亿元，同比+4.8%；毛利润39.24亿元，对应毛利率52.2%，同比+5.6ppt；税前利润为24.20亿元，同比+27.24%；实现净利润18.94亿元，同比+27.02%。增长主要受益于诺和诺德UBT251授权费的一次性...
Source Link联邦制药盘中涨超6%，截至发稿，股价上涨4.08%，现报17.18港元，成交额1.99亿港元。近日，联邦制药发布2025年上半年业绩。中金指出，25H1公司营业收入75.19亿元，同比+4.8%；毛利润39.24亿元，对应毛利率52.2%，同比+5.6ppt；税前利润为24.20亿元，同比+27.24%；实现净利润18.94亿元，同比+27.02%。增长主要受益于诺和诺德UBT251授权费的一次性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.